Literature DB >> 18317771

Molecular aspects of osteopathy in type 1 Gaucher disease: correlation between genetics and bone density.

Efrat Arnheim1, Gaya Chicco, Mici Phillips, Ehud Lebel, A Joseph Foldes, Menachem Itzchaki, Deborah Elstein, Ari Zimran, Gheona Altarescu.   

Abstract

Bone-related complications in Gaucher disease are considered to be poorly responsive to specific enzyme replacement therapy. Polymorphisms of candidate genes associated with low bone density were investigated to see whether they are correlated with bone mineral density (BMD) and bone involvement in Gaucher disease. Genotyping for polymorphisms in candidate genes (interleukins 1alpha and 1beta, interleukin-1 receptor antagonist; cytochrome P450; collagen 1A1; low-density Lipoprotein Receptor; bone morphogenic protein 4; vitamin D receptor; and estrogen receptor 2beta) were performed using standard methodologies. BMD was measured by dual energy X-ray absorptiometry (DXA). One hundred and ninety-four patients and 100 controls were genotyped for the above polymorphisms. Thirteen haplotypes were obtained, with several correlations with BMD in patients; also, a haplotype (T889-T3954-C511-240VNTR of IL1) was significantly correlated with T-scores and Z-score for femur neck and lumbar spine (p = 0.01) in patients. Haplotypes of bone-specific candidate genes associated with BMD may predict severity of these features in Gaucher disease.

Entities:  

Mesh:

Year:  2008        PMID: 18317771     DOI: 10.1007/s00296-008-0550-7

Source DB:  PubMed          Journal:  Rheumatol Int        ISSN: 0172-8172            Impact factor:   2.631


  18 in total

1.  Outcome of total hip arthroplasty in patients with Gaucher disease.

Authors:  E Lebel; M Itzchaki; I Hadas-Halpern; A Zimran; D Elstein
Journal:  J Arthroplasty       Date:  2001-01       Impact factor: 4.757

2.  Two new single-nucleotide polymorphisms in the COL1A1 upstream regulatory region and their relationship to bone mineral density.

Authors:  Natalia Garcia-Giralt; Xavier Nogués; Anna Enjuanes; Jordi Puig; Leonardo Mellibovsky; Anne Bay-Jensen; Ramon Carreras; Susana Balcells; Adolfo Díez-Pérez; Daniel Grinberg
Journal:  J Bone Miner Res       Date:  2002-03       Impact factor: 6.741

3.  Decreased spinal and femoral neck volumetric bone mineral density (BMD) in men with primary osteoporosis and their first-degree male relatives: familial effect on BMD in men.

Authors:  Bircan Erbas; Sonia Ristevski; Cathy Poon; Stella Yeung; Peter R Ebeling
Journal:  Clin Endocrinol (Oxf)       Date:  2007-01       Impact factor: 3.478

4.  LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development.

Authors:  Y Gong; R B Slee; N Fukai; G Rawadi; S Roman-Roman; A M Reginato; H Wang; T Cundy; F H Glorieux; D Lev; M Zacharin; K Oexle; J Marcelino; W Suwairi; S Heeger; G Sabatakos; S Apte; W N Adkins; J Allgrove; M Arslan-Kirchner; J A Batch; P Beighton; G C Black; R G Boles; L M Boon; C Borrone; H G Brunner; G F Carle; B Dallapiccola; A De Paepe; B Floege; M L Halfhide; B Hall; R C Hennekam; T Hirose; A Jans; H Jüppner; C A Kim; K Keppler-Noreuil; A Kohlschuetter; D LaCombe; M Lambert; E Lemyre; T Letteboer; L Peltonen; R S Ramesar; M Romanengo; H Somer; E Steichen-Gersdorf; B Steinmann; B Sullivan; A Superti-Furga; W Swoboda; M J van den Boogaard; W Van Hul; M Vikkula; M Votruba; B Zabel; T Garcia; R Baron; B R Olsen; M L Warman
Journal:  Cell       Date:  2001-11-16       Impact factor: 41.582

5.  Bone mineral density in sclerosteosis; affected individuals and gene carriers.

Authors:  Jessica C Gardner; Rutger L van Bezooijen; Benjamin Mervis; Neveen A T Hamdy; Clemens W G M Löwik; Herman Hamersma; Peter Beighton; Socrates E Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  2005-09-27       Impact factor: 5.958

6.  The IL-1 gene family and bone involvement in celiac disease.

Authors:  M L Moreno; J B A Crusius; A Cherñavsky; E Sugai; A Sambuelli; H Vazquez; E Mauriño; A S Peña; J C Bai
Journal:  Immunogenetics       Date:  2005-09-29       Impact factor: 2.846

7.  Bone density in Type 1 Gaucher disease.

Authors:  G M Pastores; S Wallenstein; R J Desnick; M M Luckey
Journal:  J Bone Miner Res       Date:  1996-11       Impact factor: 6.741

8.  A genetic association between juvenile rheumatoid arthritis and a novel interleukin-1 alpha polymorphism.

Authors:  T L McDowell; J A Symons; R Ploski; O Førre; G W Duff
Journal:  Arthritis Rheum       Date:  1995-02

9.  Estrogen receptor beta polymorphisms are associated with bone mass in women and men: the Framingham Study.

Authors:  Amanda M Shearman; David Karasik; Kristen M Gruenthal; Serkalem Demissie; L Adrienne Cupples; David E Housman; Douglas P Kiel
Journal:  J Bone Miner Res       Date:  2003-12-22       Impact factor: 6.741

10.  Skeletal complications of Gaucher disease.

Authors:  D W Stowens; S L Teitelbaum; A J Kahn; J A Barranger
Journal:  Medicine (Baltimore)       Date:  1985-09       Impact factor: 1.889

View more
  4 in total

Review 1.  Gaucher disease: a systematic review and meta-analysis of bone complications and their response to treatment.

Authors:  Siavash Piran; Dominick Amato
Journal:  J Inherit Metab Dis       Date:  2010-03-25       Impact factor: 4.982

2.  Effect of vitamin D receptor (VDR) genotypes on the risk for osteoporosis in type 1 Gaucher disease.

Authors:  Allen Greenwood; Deborah Elstein; Ari Zimran; Gheona Altarescu
Journal:  Clin Rheumatol       Date:  2010-04-25       Impact factor: 2.980

3.  Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher disease type 1.

Authors:  Anca Zimmermann; Radu A Popp; Heidi Rossmann; Simona Bucerzan; Ioana Nascu; Daniel Leucuta; Matthias M Weber; Paula Grigorescu-Sido
Journal:  Ther Clin Risk Manag       Date:  2018-10-24       Impact factor: 2.423

4.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.